Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia 6Leukemia, Hairy Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 3Recurrence 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Cerebral Palsy 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × immunotoxin HA22 × Clear all
NCT00462189 2007-04-18

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Recurrence

NCT00457860 2007-04-17

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡